~~<i id='B64FE1D929'><strike id='B64FE1D929'><tt id='B64FE1D929'><pre id='B64FE1D929'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

explore

author：Wikipedia 2025-09-28 01:39:14 - browse：485

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen
Next article： Alabama frozen embryo ruling has major implications for IVF clinics

hotspot

focus

leisure time

focus

Photoillustration:AlexHogan/STAT;Sourcephoto:AFPviaGettyOnedaylastAugust,astheystruggledtofigureoutw

WSS

STAT Summit: Biotech founders on deal

A new nitrogen execution bill also undermines medical licensing

Beam Therapeutics to lay off 20% of its staff, re

The explosion of genetic testing requires a new approach

Lawmakers consider Medicare pay reforms for doctors

Why palliative psychiatry is worth discussing

entertainment

explore

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

STAT Summit: GSK CEO on pharma giant's new direction

ChatGPT in medicine: STAT answers readers' burning questions

He's a Nobel laureate. Critics say he was misleading on Covid

Psychedelics group wrestles with new pharma identity

HHS leader on health, climate change and biopharma emissions

George Santos makes 1st court appearance after pleading not guilty to 13 counts

FDA struggles to regulate food additives, sometimes for decades

As demand for Covid shots wanes, Moderna seeks its next success

NIH study of ME/CFS points to clear biological hallmarks

hotspot

Senate committee scrutinizes Medicare Advantage brokers

Solve the antibiotic resistance crisis with preventive drugs

Solve the antibiotic resistance crisis with preventive drugs

R1 RCM gets $5.8 billion buyout offer from private equity firm

Alabama hospital puts IVF treatments on hold

Medicare inequities exacerbate Puerto Rico’s health disparities

focus

leisure time

focus

focus